Data gathered: April 26
AI Stock Analysis - Geron (GERN)
Analysis generated October 29, 2024. Powered by Chat GPT.
Geron Corporation is a biotechnology company focused on the development and commercialization of innovative therapeutic treatments. The company's primary product candidate, imetelstat, is a first-in-class telomerase inhibitor in various stages of clinical trials for hematologic myeloid malignancies. Geron has established a robust pipeline and strategic collaborations that strengthen its prospects in a competitive market. Despite facing numerous challenges and fluctuations in its financial performance, Geron's focus on pioneering treatments places it in a unique position within the healthcare sector.
Stock Alerts - Geron (GERN)
 |
Geron | April 25 News Alert: Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights – GERN |
|
Geron | April 21 Price is up by 10.2% in the last 24h. |
|
Geron | April 15 Price is down by -7.2% in the last 24h. |
|
Geron | April 10 Price is down by -5% in the last 24h. |
Alternative Data for Geron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 17 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 59 | Sign up | Sign up | Sign up |
| Patents | 30 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 35 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 21,271 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 383 | Sign up | Sign up | Sign up |
About Geron
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| Price | $1.42 |
| Target Price | Sign up |
| Volume | 6,360,000 |
| Market Cap | $904M |
| Year Range | $1.24 - $4.75 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Earnings Date | May 7 '25 |
| Industry | Biotechnology |
In the news
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERNApril 25 - GlobeNewswire |
|
 |
Invesco Ltd. Sells 385,925 Shares of Geron Co. (NASDAQ:GERN)April 25 - ETF Daily News |
|
JPMorgan Chase & Co. Decreases Position in Geron Co. (NASDAQ:GERN)April 25 - ETF Daily News |
GERN IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Geron Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GERNApril 24 - Finnhub |
|
Investors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class Action - GERNApril 24 - Finnhub |
|
ROSEN, A LEADING NATIONAL FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERNApril 24 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 28M | 36M | -7.6M | -26M | -28M | -0.040 |
| Q2 '24 | 880,000 | 39M | -39M | -67M | -69M | -0.100 |
| Q1 '24 | 300,000 | 27M | -30M | -55M | -56M | -0.090 |
| Q4 '23 | 23,000 | 22M | -24M | -52M | -54M | -0.090 |
| Q3 '23 | 160,000 | 18M | -20M | -45M | -48M | -0.080 |
Insider Transactions View All
| SCARLETT JOHN A filed to buy 12,500 shares at $1.8. March 3 '25 |
| Samuels Scott Alan filed to buy 26,682 shares at $1.6. March 3 '25 |
| Ziegler James filed to buy 100,000 shares at $1.6. March 3 '25 |
Similar companies
Read more about Geron (GERN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Geron?
The Market Cap of Geron is $904M.
When does Geron report earnings?
Geron will report its next earnings on May 7 '25.
What is the current stock price of Geron?
Currently, the price of one share of Geron stock is $1.42.
How can I analyze the GERN stock price chart for investment decisions?
The GERN stock price chart above provides a comprehensive visual representation of Geron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Geron shares. Our platform offers an up-to-date GERN stock price chart, along with technical data analysis and alternative data insights.
Does GERN offer dividends to its shareholders?
As of our latest update, Geron (GERN) does not offer dividends to its shareholders. Investors interested in Geron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Geron?
Some of the similar stocks of Geron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.